Jump to main content
Jump to site search


Regression of murine Ehrlich ascites carcinoma using synthesized cobalt complex

Abstract

Cisplatin as a mean chemotherapy had nephro-toxicity and so tray to develop novel antitumor drug based on combination of cobalt metal ion with organic moiety. Antitumor activity of the complex was tested in vitro and in vivo against murine Ehrlich ascites carcinoma (EAC). Antioxidant capacity and nucleic acids content were determined. Cobalt(II) diacetyl monoxime-2-hydrazinopyridine complex significantly diminished tumor load. It decreased the tumor proliferation rate and increased the life span of EAC-bearing mice obviously. It reversed back the haematological parameters towards normal, reduced liver enzymes and urea, increased albumin and total protein. Antioxidant parameters levels were reversed towards normal. An assessment was conducted by comparing these results with those obtained using the standard drug cisplatin. The results suggest that the cobalt complex can be considered as a potent anticancer agent as it showed appreciated antitumor activity in EAC-bearing mice that is almost analogous to that of the reference standard, cisplatin.

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 06 Nov 2016, accepted on 15 Mar 2017, published on 15 Mar 2017 and first published online on 15 Mar 2017


Article type: Research Article
DOI: 10.1039/C6MD00618C
Citation: Med. Chem. Commun., 2017, Accepted Manuscript
  •   Request permissions

    Regression of murine Ehrlich ascites carcinoma using synthesized cobalt complex

    E. A. Saad, M. Hassanien, H. El-Mezayen and N. M. ELmenawy, Med. Chem. Commun., 2017, Accepted Manuscript , DOI: 10.1039/C6MD00618C

Search articles by author